Loading…
MINT-HYDROCHLOROTHIAZIDE is a brand name for Hydrochlorothiazide, supplied as a tablet. The medicine, its uses, side effects and dosage are the same regardless of brand.
Used for: AND CLINICAL USE .............................................................. 3 CONTRAINDICATIONS ................................................................................... 4 WARNINGS AND PRECAUTIONS ................................................................. 4 ADVERSE REACTIONS…
Verbatim from this product's HC label. Tap a section to expand.
MINT-HYDROCHLOROTHIAZIDE (hydrochlorothiazide), as all diuretics, is contraindicated in anuria. MINT-HYDROCHLOROTHIAZIDE should be discontinued if increasing azotemia and oliguria occur during treatment of severe progressive renal disease.
MINT-HYDROCHLOROTHIAZIDE is contraindicated in persons known to be sensitive to hydrochlorothiazide or to other sulfonamide-derived drugs. Patients who are hypersensitive to any ingredient in the formulation of MINT- HYDROCHLOROTHIAZIDE or component of the container.
For a complete listing, see the DOSAGE FORMS, COMPOSITION AND PACKAGING section of the product monograph. WARNINGS AND PRECAUTIONS General Patients on long therapy with hydrochlorothiazide are required to be on potassium rich diet. Periodic determinations of serum electrolytes to detect possible electrolyte imbalance should be performed.
The antihypertensive effects of the drug may be enhanced in the postsympathectomy patient.
Carcinogenesis and Mutagenesis Non-melanoma skin cancer:
An increased risk of non-melanoma skin cancer (NMSC) [basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) of the skin] after hydrochlorothiazide therapy was reported in some epidemiological studies. The risk may be higher with increasing cumulative use.
The certainty of the evidence was assessed by Health Canada (see ADVERSE REACTIONS, Post Market Adverse Drug Reactions). The photosensitizing action of hydrochlorothiazide may be a possible mechanism for NMSC (see TOXICOLOGY, Carcinogenicity – Hydrochlorothiazide).
Patients taking hydrochlorothiazide should be informed of the potential risk of NMSC and advised to regularly check their skin for new lesions as well as changes to existing ones and promptly report any suspicious skin lesions. g. a broad-spectrum sunscreen with a SPF of 30 or higher, clothing, and a hat) when exposed to minimize the risk of skin cancer.
) (see ADVERSE REACTIONS, Post Market Adverse Drug Reactions). Cardiovascular MINT-HYDROCHLOROTHIAZIDE Product Monograph Page 5 of 25 No data available. Ear/Nose/Throat No data available.
Endocrine and Metabolism Calcium:
Calcium excretion is decreased by thiazides.
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Other brands of Hydrochlorothiazide in Canada.
Know a brand we are missing in Canada? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
Chloride:
Chloride deficiency is generally mild and does not require specific treatment except under special conditions such as renal or/and hepatic disease.
Dilutional Hyponatremia:
Dilutional hyponatremia may occur in edematous patients in hot weather; appropriate therapy is water restriction rather than administration of salt except when hyponatremia is life threatening. In actual salt depletion, appropriate replacement is the therapy of choice.
Fluid and electrolyte imbalance:
All patients receiving thiazide should be observed for clinical signs of fluid or electrolyte imbalance: namely hyponatremia, hypochloremic alkalosis, and hypokalemia. Serum and urine electrolyte determinations are particularly important when the patient is vomiting excessively, or receiving parenteral fluids.
Warning signs of serum electrolyte imbalance, irrespective of cause are: dryness of mouth, thirst, weakness, lethargy, drowsiness, restlessness, muscle pains or cramps, muscular fatigue, hypotension, oliguria, tachycardia, and gastrointestinal disturbances such as nausea and vomiting.
Serum electrolytes may also be influenced by medication such as digitalis.
Hyperuricemia:
Hyperuricemia may occur or frank gout may be precipitated in certain patients receiving thiazide therapy.
Hypokalemia:
Hypokalemia may develop, especially with rapid diuresis, when severe cirrhosis is present or during concomitant use of corticosteroids or ACTH. Deficient oral electrolyte intake will also contribute to hypokalemia. g. increased ventricular irritability).
Hypokalemia may be avoided or treated by the use of potassium supplements.
Insulin:
Insulin requirements in diabetic patients may be increased, decreased, or remain unchanged. Latent diabetes mellitus may become manifest during thiazide therapy. Concomitant therapy with lithium is not recommended with diuretics because of the reduction of renal clearance of lithium and therefore an added risk of lithium toxicity.
Parathyroid gland:
Pathological changes in the parathyroid gland with hypercalcemia and hypophosphatemia have been observed in a few patients on prolonged thiazide therapy. The common complications of hyperparathyroidism such as renal lithiasis, bone resorption, and peptic ulceration have not been reported.
Use of thiazides should be discontinued before carrying out tests for parathyroid function.
Protein bound iodine (PBI):
Thiazides may decrease serum PBI levels without signs of thyroid MINT-HYDROCHLOROTHIAZIDE Product Monograph Page 6 of 25 disturbance. Gastrointestinal Non-specific small bowel lesions consisting of stenosis with or without ulceration, may occur in association with the administration of enteric coated potassium salts, alone or with oral diuretics.
These small bowel lesions have caused obstruction, hemorrhage and perforation. Surgery was frequently required and deaths have occurred. Available information tends to implicate enteric coated potassium salts, although lesions of this type also occur spontaneously.
Such preparations should be used only when adequate dietary supplementation is not practical, and should be discontinued immediately if abdominal pain, distention, nausea, vomiting or gastrointestinal bleeding occur. Genitourinary No data available.
Hematologic No data available. Hepatic/biliary/Pancreatic MINT-HYDROCHLOROTHIAZIDE should be used with caution in […]
+8 more